Navidea biopharmaceuticals receives acceptance letter from nyse american

Dublin, ohio--(business wire)--as previously disclosed, on january 28, 2022, navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received a notification from the nyse american stating that the company was not in compliance with the $6.0 million stockholders' equity requirement of section 1003(a)(iii) of the nyse american company guide. as required by the nyse americ
NAVB Ratings Summary
NAVB Quant Ranking